• The group of patients where this issue is of prime importance is when considering those groups of patients with underlying Atrial Fibrillation (AF) and prosthetic heart valves. The risk of embolisation is increased with mitral valve prostheses, caged ball devices and multiple prosthetic valves.
• It is equally of paramount importance to calculate the thromboembolic risk by applying the CHADS2 score. If the score is 2 or above, we should consider bridging anticoagulation with unfractionated heparin or low molecular weight heparin [2] . Heparin has the advantages where regular monitoring is required and can be reversed rapidly in the event of intracranial bleeding. We recommend a multidisciplinary approach including cardiology colleagues when determining the best form of anticoagulation in such cases. Reply Re: Anticoagulation in acute stroke patients with AF and prosthetic valves SIR-We acknowledge the useful points made by Naqvi and Kausar in response to our review of anticoagulation after acute cardioembolic stroke. Knowing which prosthetic heart valves are highly thrombogenic helps to inform the risk-benefit decision about how urgently to pursue a policy of anticoagulation in all patients at risk of bleeding. We agree that such decisions are best made in conjunction with a Cardiologist. The topic review by Crawley et al. in 2000 has useful information on prosthetic heart valves and recommends withholding anticoagulation for a period of 4-6 weeks after spontaneous intracranial haemorrhage. However, the risk-benefit decision in the case of infarction is different and may allow earlier re-anticoagulation. The CHADS2 score, among others, does provide an estimate of the thromboembolic risk due to AF in the long term. However, we are unaware of any studies demonstrating it's validity to guide anticoagulation in the acute setting. If unfractionated heparin is used as a bridging therapy, regular monitoring of the degree of anticoagulation is, of course, recommended.
